EVgo Inc. (EVGO): Nasdaq/NYSE listing notice — EVgo receives Nasdaq deficiency notice for audit committee vacancy; cure period through mid-2024

EVgo Inc.

Non-compliance due to Badar Khan's departure from the Audit Committee.
Cure period ends at earlier of next annual meeting or Aug 1, 2024.
If 2024 annual meeting before Jan 29, 2024, compliance due by Jan 29, 2024.
Company evaluating committee membership and intends to regain compliance.
Notice has no immediate effect on listing or trading of EVGO or EVGOW.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

EVgo Inc. received a nasdaq noncompliance notice notice regarding audit committee (rules 5605).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: audit committee
Rules: 5605

Exact text from the filing

August 8, 2023, the Company received a written notice (the “ Letter ”) from Nasdaq’s Listing Qualifications Department confirming that, as a result of Mr. Badar Khan’s departure from the Audit Committee, the Company is no longer in compliance with Nasdaq’s audit committee composition requirement set forth in Nasdaq Listing Rule 5605. The Letter is only a notification of deficiency and has no current effect on the listing or trading of the Company’s securities on Nasdaq. The Letter states that, consistent with Nasdaq Listing Rule 5605(c)(4), Nasdaq will provide the Company with a cure period in

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

EVgo Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-089806

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.